CL2023001740A1 - Dosificación de fedratinib - Google Patents

Dosificación de fedratinib

Info

Publication number
CL2023001740A1
CL2023001740A1 CL2023001740A CL2023001740A CL2023001740A1 CL 2023001740 A1 CL2023001740 A1 CL 2023001740A1 CL 2023001740 A CL2023001740 A CL 2023001740A CL 2023001740 A CL2023001740 A CL 2023001740A CL 2023001740 A1 CL2023001740 A1 CL 2023001740A1
Authority
CL
Chile
Prior art keywords
fedratinib
dosage
cyp2c19
cyp3a4
patients
Prior art date
Application number
CL2023001740A
Other languages
English (en)
Inventor
Krishna Gopal
Ogasawara Ken
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of CL2023001740A1 publication Critical patent/CL2023001740A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona métodos para tratar trastornos mieloproliferativos en pacientes que reciben simultáneamente un inhibidor dual de CYP2C19 y CYP3A4.
CL2023001740A 2020-12-16 2023-06-14 Dosificación de fedratinib CL2023001740A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063126289P 2020-12-16 2020-12-16

Publications (1)

Publication Number Publication Date
CL2023001740A1 true CL2023001740A1 (es) 2023-11-10

Family

ID=80050729

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001740A CL2023001740A1 (es) 2020-12-16 2023-06-14 Dosificación de fedratinib

Country Status (11)

Country Link
US (1) US20240058336A1 (es)
EP (1) EP4262770A1 (es)
JP (1) JP2024501640A (es)
KR (1) KR20230142468A (es)
CN (1) CN116829136A (es)
AU (1) AU2021401681A1 (es)
CA (1) CA3199509A1 (es)
CL (1) CL2023001740A1 (es)
IL (1) IL303118A (es)
MX (1) MX2023006939A (es)
WO (1) WO2022132933A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
KR20210102192A (ko) 2018-09-25 2021-08-19 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
US20230250068A1 (en) 2019-02-12 2023-08-10 Inpact Biomedicines, Inc. Crystalline forms of a jak2 inhibitor

Also Published As

Publication number Publication date
EP4262770A1 (en) 2023-10-25
US20240058336A1 (en) 2024-02-22
AU2021401681A1 (en) 2023-06-22
CA3199509A1 (en) 2023-06-23
IL303118A (en) 2023-07-01
JP2024501640A (ja) 2024-01-15
KR20230142468A (ko) 2023-10-11
CN116829136A (zh) 2023-09-29
MX2023006939A (es) 2023-08-08
WO2022132933A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
CO2020012588A2 (es) Composiciones de inhibidores de shp2, métodos para tratar el cáncer y metodos para identificar a un sujeto con mutaciones de shp2
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2019001674A1 (es) Inhibidores de imidazopirazina de tirosina quinasa de bruton.
MX2020009773A (es) Terapia de combinacion.
NZ750974A (en) Antibody and checkpoint inhibitor combination therapy
CL2022000922A1 (es) Aminas bicíclicas como inhibidores de la cdk2.
DOP2014000274A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CR20150242A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
TW201613644A (en) Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
EA201690746A1 (ru) Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CO2017004517A2 (es) Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration
BR112022014058A2 (pt) Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
CO2020014599A2 (es) Métodos para tratar cáncer
CO6280510A2 (es) Pirimidil ciclopentanos hidroxilados como inhibidores de akt proteina quinasa
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
CO2021015622A2 (es) Terapias de combinación que comprenden inhibidores de apremilast y tyk2
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CO2022000270A2 (es) Inhibidores de enzimas
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
BR112019008241A2 (pt) tratamento do prurigo nodular